Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Inosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | DPP4 | P27487 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.67 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.67 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.67 |
| ▸ | GAPDH | P04406 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
| ▸ | STAT6 | P42226 | 1/20 | 0.67 |
| ▸ | PI4KA | P42356 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.67 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.67 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inosine SCHEMBL5896867 | 1.00 | SLC29A1 (0.67) | SLC29A1ADORA3ADORA1SMN1; SMN2DPP4 | |
| Inosine SCHEMBL298755 | 0.94 | SLC29A1 (0.75) | SLC29A1ADORA3ADORA1SMN1; SMN2DPP4 | |
| Inosine SCHEMBL6748954 | 0.94 | SLC29A1 (0.75) | SLC29A1ADORA3ADORA1SMN1; SMN2DPP4 | |
| Inosine SCHEMBL4110068 | 0.94 | SLC29A1 (0.75) | SLC29A1ADORA3ADORA1SMN1; SMN2DPP4 | |
| Inosine SCHEMBL15804 | 0.94 | SLC29A1 (0.75) | SLC29A1ADORA3ADORA1SMN1; SMN2DPP4 | |
| Inosine SCHEMBL18653532 | 0.94 | SLC29A1 (0.75) | SLC29A1ADORA3ADORA1SMN1; SMN2DPP4 | |
| Inosine SCHEMBL330178 | 0.94 | SLC29A1 (0.75) | SLC29A1ADORA3ADORA1SMN1; SMN2DPP4 | |
| Inosine SCHEMBL2046912 | 0.94 | SLC29A1 (0.75) | SLC29A1ADORA3ADORA1SMN1; SMN2DPP4 | |
| Inosine SCHEMBL12763613 | 0.94 | SLC29A1 (0.75) | SLC29A1ADORA3ADORA1SMN1; SMN2DPP4 | |
| Inosine SCHEMBL20138477 | 0.94 | SLC29A1 (0.75) | SLC29A1ADORA3ADORA1SMN1; SMN2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049301-B2 | Quercetin derivatives and their medical usages | ACADEMY OF MILITARY MEDICAL SCIENCES INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY (CN) | 2006-05-23 | — | — | US | disclosed |
| US-20040132671-A1 | Quercetin derivatives and their medical usages | ACADEMY OF MILITARY MEDICAL SCIENCES INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132671-A1 | Quercetin derivatives and their medical usages | HTR1A, HTR2A, HTR5A | SLC29A1 854/4885ADORA3 134/4885ADORA1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.